CLXConsumer Defensive · Household & Personal ProductsThe 19 Wall Street analysts covering The Clorox Co. hold a median 12-month price target of $100 — -6.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores The Clorox Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (84): The business earns solid, repeatable profits on what it owns.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −6.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Citigroup | Maintains | Neutral | $97 → $100 |
| 4 Aug 2026 | Evercore ISI Group | Maintains | Underperform | $98 → $99 |
| 4 Aug 2026 | JP Morgan | Maintains | Underweight | $92 → $95 |
| 4 Aug 2026 | UBS | Maintains | Neutral | $100 → $105 |
| 4 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $95 → $102 |
| 28 July 2026 | Jefferies | Downgrade | Hold | $125 → $98 |
| 23 July 2026 | Evercore ISI Group | Maintains | Underperform | $110 → $98 |
| 23 July 2026 | Evercore ISI Group | Maintains | Underperform | — |
| 21 July 2026 | Barclays | Maintains | Underweight | $85 → $86 |
| 21 July 2026 | Barclays | Maintains | Underweight | — |
| 20 July 2026 | BNP Paribas | Maintains | Neutral | $97 → $95 |
| 20 July 2026 | BNP Paribas | Maintains | Neutral | — |
| 16 July 2026 | JP Morgan | Maintains | Underweight | — |
| 16 July 2026 | JP Morgan | Maintains | Underweight | $95 → $92 |
| 16 July 2026 | UBS | Maintains | Neutral | — |
| 16 July 2026 | UBS | Maintains | Neutral | $96 → $100 |
| 18 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 May 2026 | Barclays | Maintains | Underweight | — |
| 1 May 2026 | Citigroup | Maintains | Neutral | — |
| 1 May 2026 | Evercore ISI Group | Maintains | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 54% of US stocks
Cheaper than 1% of US stocks
Cheaper than 21% of US stocks
Higher than 24% of US stocks
Higher than 10% of US stocks
Higher than 52% of US stocks
Higher than 69% of US stocks
Higher than 67% of US stocks
Higher than 98% of US stocks
Higher than 89% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Clorox Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Clorox's acquisition of GOJO is expected to boost fiscal 2027 sales. However, the item notes that inflation, acquisition costs, and margin pressure could limit underlying growth.
Why it matters — A CLX watcher would care because the GOJO deal presents a potential sales catalyst for fiscal 2027, yet cost and margin headwinds may temper its benefit.
Zacks Investment Research reports that Clorox's growth is being led by its GOJO hand-sanitizer business, but the company faces margin pressure, muted core demand, and inflation risks. The article notes investors are focused on whether a durable recovery can be achieved.
Why it matters — A CLX watcher would care because the piece highlights that GOJO-driven growth is being offset by margin pressure, weak core demand, and inflation risks, which bear on the company's recovery prospects.
Clorox stock rose 13.1% over a month, but the rebound faces margin pressure, muted underlying demand, and weaker earnings revisions. The company has some tailwinds from GOJO and ERP initiatives, yet these are weighed against ongoing challenges.
Why it matters — CLX watchers would care because the recent share-price gain may be undermined by persistent profit-margin strain, soft demand, and downward earnings revisions that could limit the sustainability of the rebound.
Seeking Alpha reiterates a Hold rating on The Clorox Company, noting that the current valuation requires unsustainably high free cash flow growth. While recent positives include the GOJO acquisition and ERP rollout, organic revenue growth remains limited after adjusting for these factors, and the balance sheet is heavily leveraged post-acquisition, raising dividend sustainability concerns.
Why it matters — This item highlights valuation, leverage, and dividend sustainability concerns that CLX watchers would need to weigh against the company's recent acquisitions and operational improvements.
The Clorox Co. announced that its Chair and CEO Linda Rendle and CFO Luc Bellet will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Wednesday, September 9, in Boston.
Why it matters — CLX watchers would care because the company's top executives will be publicly discussing the business at a prominent investor conference.
The 19 Wall Street analysts covering The Clorox Co. have a median 12-month price target of $100, with estimates ranging from $77 to $154. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering The Clorox Co., 1 rate it a Buy, 14 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks The Clorox Co. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, The Clorox Co. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (84 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies -6.3% from the last close, and Ticker Nerd's factor model ranks The Clorox Co. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Clorox Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $77 to $154 over the next 12 months.
The Clorox Co. returned -6.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Clorox Company is a consumer products manufacturer focused on household, health, and lifestyle brands used in everyday cleaning and personal care. Based in Oakland, California and founded in 1913, the company operates through four main segments: Health and Wellness, Household, Lifestyle, and International.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook". Zacks reports that Clorox's acquisition of GOJO is expected to boost fiscal 2027 sales. However, the item notes that inflation, acquisition costs, and margin pressure could limit underlying growth.
The Clorox Company is a consumer products manufacturer focused on household, health, and lifestyle brands used in everyday cleaning and personal care. Based in Oakland, California and founded in 1913, the company operates through four main segments: Health and Wellness, Household, Lifestyle, and International. Its Health and Wellness portfolio includes cleaning and disinfecting products, bleach, laundry additives, and professional hygiene solutions used in homes and commercial settings. The Household segment covers trash bags, food storage, cat litter, and related home care products. Lifestyle offerings include food dressings, sauces, and water filtration, while the International segment distributes many of these brands globally. The Clorox Company owns a broad range of well-known names across cleaning, food, personal care, and filtration, serving both consumer and professional customers worldwide and playing a significant role in the consumer staples and household and personal products industry.
CEO Ms. Linda J. Rendle · 9,200 employees · United States · https://www.thecloroxcompany.com